Dyslipidaemia in diabetes.
Patel
Jigisha
J
Royal Free and UCL Medical School, Division of Medicine, Centre for Clinical Science and Technology, London, UK.
D001384:Azetidines / Q000627:therapeutic use; D001629:Bezafibrate / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy / Q000628:therapy*; D003925:Diabetic Angiopathies; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy / Q000628:therapy*; D000069438:Ezetimibe; D005395:Fish Oils / Q000627:therapeutic use; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use
D001384:Azetidines; D005395:Fish Oils; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D000069438:Ezetimibe; D015248:Gemfibrozil; D001629:Bezafibrate